Bridgeway Capital Management’s Tourmaline Bio TRML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-15,267
| Closed | -$310K | – | 1253 |
|
|
2024
Q4 | $310K | Sell |
15,267
-2,000
| -12% | -$40.6K | 0.01% | 915 |
|
|
2024
Q3 | $444K | Hold |
17,267
| – | – | 0.01% | 892 |
|
|
2024
Q2 | $222K | Hold |
17,267
| – | – | 0.01% | 1040 |
|
|
2024
Q1 | $395K | Sell |
17,267
-14,850
| -46% | -$340K | 0.01% | 984 |
|
|
2023
Q4 | $841K | Buy |
32,117
+1,999
| +7% | +$52.3K | 0.02% | 799 |
|
|
2023
Q3 | $846K | Buy |
30,118
+15,188
| +102% | +$427K | 0.02% | 752 |
|
|
2023
Q2 | $454K | Buy |
14,930
+2,140
| +17% | +$65.1K | 0.01% | 929 |
|
|
2023
Q1 | $240K | Sell |
12,790
-3,650
| -22% | -$68.6K | 0.01% | 1069 |
|
|
2022
Q4 | $168K | Buy |
16,440
+15,290
| +1,330% | +$156K | ﹤0.01% | 1129 |
|
|
2022
Q3 | $30K | Buy |
+1,150
| New | +$30K | ﹤0.01% | 1374 |
|